治疗膀胱过度活动症的新型肾上腺素β_(3)受体激动剂:vibegron  

A novel β_(3) adrenergic receptor agonist for treating overactive bladder:vibegron

作　　者：杨君义 YANG Jun-yi(Department of Pharmacy,Central Hospital of Linyi City,Linyi SHANDONG 276400,China)

机构地区：[1]临沂市中心医院药学部,山东临沂276400

出　　处：《中国新药与临床杂志》2022年第3期143-146,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：vibegron(Vib)为一种新型肾上腺素β_(3)受体激动剂,可兴奋膀胱内肾上腺素β_(3)受体,增加膀胱容量,延长排尿间隔时间。Vib已于2020年12月获美国食品和药物管理局批准用于治疗成人伴尿急、尿频及尿失禁的膀胱过度活动症。临床研究表明,Vib可明显降低患者日排尿次数和尿失禁发作次数,而且疗效优于抗胆碱能药物托特罗定。常见不良事件包括头痛、尿路感染、鼻咽炎、腹泻、恶心及上呼吸道感染等。Vibegron(Vib)is a novel β_(3) adrenergic receptor agonist.It can stimulate β_(3) adrenergic receptors in the bladder and increase the bladder volume,which results in prolongation of the interval between voids.Vib has been approved for the treatment of overactive bladder with symptoms of urge urinary incontinence,urgency and urinary frequency in adults by the U.S.Food and Drug Administration in December,2020.Clinical studies have shown that Vib can significantly reduce daily urination and urinary incontinence episodes,and is superior to anticholinergic drug tolterodine.The common adverse events include headache,urinary tract infection,nasopharyngitis,diarrhea,nausea,and upper respiratory tract infection.

关 键 词：vibegron 膀胱 过度活动性 肾上腺素能β-3受体激动剂 

分 类 号：R694[医药卫生—泌尿科学] R971.94[医药卫生—外科学]